ArticleMolecular biology reports2026
The impact of the telomerase inhibitor on the Wnt signaling pathway in breast cancer and breast cancer stem cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundBreast cancer remains one of the leading causes of cancer-related mortality in women worldwide. Breast cancer stem cells (BCSCs) contribute to tumor initiation, metastasis, recurrence, and resistance to therapy. The Wnt signaling pathway is a major regulator of stemness properties and is associated with poor clinical outcomes. BIBR1532 is a selective telomerase inhibitor widely used in cancer research due to its ability to inhibit telomerase activity in tumor cells with minimal toxicity in normal tissues. This study aimed to investigate the effects of BIBR1532 on the Wnt signaling pathway in breast cancer cells and BCSCs.
methodsCytotoxicity of BIBR1532 was evaluated in MCF-7 breast cancer cells, MCF10A normal breast epithelial cells, and BCSCs using a 48-hour treatment. IC₅₀ values were calculated, and apoptosis induction was assessed. Changes in the expression of Wnt pathway-related genes following BIBR1532 treatment were analyzed using RT-qPCR.
resultsThe IC₅₀ values of BIBR1532 at 48 h were 35.29 µM for MCF-7, 28.16 µM for MCF10A, and 30.42 µM for the BCSC line. BIBR1532 markedly induced apoptosis in MCF-7 and BCSCs, whereas minimal apoptotic changes were observed in MCF10A cells. RT-qPCR analysis revealed significant modulation of genes in the Wnt signaling pathway: several oncogenic components were downregulated, while multiple tumor-suppressive genes were upregulated. Additionally, expression changes in less-studied Wnt-related genes may provide new insights for future breast cancer research.
conclusionsBIBR1532 exerts selective cytotoxic and pro-apoptotic effects on breast cancer cells and BCSCs and modulates key components of the Wnt signaling pathway. These findings suggest that telomerase inhibition may influence stemness-related signaling in breast cancer.
Indexed as
Identifiers
41518394What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.